Enzyvant’s Path From Complete Response Letter To FDA Approval For Rethymic Included CMC Revamp
Executive Summary
Two-year journey after CRL did not start with a meeting with US FDA, but rather a ‘pause’ to better understand agency’s perspective, execs say. Firm would later develop a roadmap with FDA to overcome manufacturing issues for the the first tissue-based therapeutic approved by the agency.